NewsFlash Articles Data Fundraising Skill&API

First "AI Unicorn" Medvi Myth Reversal Unveils a Gray Pharmaceutical Supply Chain

Read this article in 14 Minutes

Medvi does not engage in any medical activities. It does not employ doctors, prescribe medication, prepare medication, or deliver goods. Its only activity is customer acquisition.

The New York Times published a major article on April 2nd, telling the story of a remote healthcare company called Medvi: Founder Matthew Gallagher used over a dozen AI tools such as ChatGPT, Claude, and Grok to build the entire company in two months and with $20,000, with his only employee being his brother. The company was sold for $400 million in 2025 and is projected to reach $1.8 billion in 2026. After reading the story, Sam Altman said, "I bet with tech company CEOs on when AI would give rise to a billion-dollar one-person company, and it seems I won. I really want to meet this person."

Four days later, the whole story fell apart.

You might think this was another "AI scam," but the truly interesting part of this story is not AI, but the complete gray pharmaceutical industry chain behind it. To understand Medvi, you must first understand what happened in the U.S. GLP-1 weight loss drug market.

GLP-1 Weight Loss Drugs: A Hundred Billion Dollar Market

GLP-1 agonist drugs (semaglutide and tirzepatide) are the most popular prescription weight loss drugs in recent years, suppressing appetite and delaying gastric emptying by mimicking the human glucagon-like peptide. In 2025, approximately 9 million people in the U.S. were using them, about 1 in every 28 adults. Just the tirzepatide (branded as Mounjaro/Zepbound) made by Lilee Pharma alone had global sales of $36.5 billion in 2025.

The issue is the price. Wegovy (injectable semaglutide for weight loss) costs about $1,349 per month, and Zepbound (injectable tirzepatide for weight loss) costs about $1,060 per month. Many American consumers want to use them but cannot afford to, especially self-pay patients not covered by insurance.

Regulatory Loophole: The Floodgates Opened by "Drug Shortages"

There is a U.S. federal law provision: when the FDA determines that a particular drug is in a "shortage" status, licensed compounding pharmacies can legally prepare a compounded version of that drug. In 2023-2024, due to a surge in demand, the FDA successively announced shortages of semaglutide and tirzepatide. The floodgates opened.

A large number of compounding pharmacies rushed in to prepare compounded versions of GLP-1, pricing them as low as $100 - $300 per month, a fraction of the brand-name drugs. Remote healthcare companies were responsible for customer acquisition and prescriptions, while compounding pharmacies handled production and delivery. A complete industry chain was formed in a few months.

In early 2025, the FDA successively ended the shortage status of the two drugs, giving compounding pharmacies a few months of transition period. According to the law, after June 2025, with very few exceptions, all GLP-1 compounded drugs were illegal. However, the market did not shrink but expanded. Many compounding pharmacies added ingredients like vitamin B12 to the drugs, claiming that adding something made them not "basic generics," attempting to circumvent the ban.

Since the beginning of this year, the FDA has started large-scale enforcement actions: issuing thousands of warning letters, and Novo Nordisk sued Hims & Hers (one of the largest telehealth platforms in the U.S.), which eventually settled with Novo Nordisk and began reselling genuine medication.

Medvi emerged during this window of opportunity.

What Exactly is Medvi

Medvi does not engage in any medical activities itself. It does not employ doctors, prescribe medication, dispense drugs, or handle shipments. The only thing it does is acquire customers.

All medical processes are outsourced to a company called OpenLoop Health. OpenLoop describes itself as a "white-label telemedicine infrastructure provider," offering a ready-to-use full-service package to anyone looking to create a telehealth brand: covering 20,000+ contracted doctors across all 50 states in the U.S., prescription processes, compliance frameworks, and a technical platform. Customers only need to set up a marketing front end to immediately start selling medication.

Consumers fill out a questionnaire on the Medvi website → OpenLoop's contracted doctors review and prescribe → Prescriptions are sent to the Triad Rx pharmacy for dispensing → Triad Rx dispenses and ships the medication. Medvi is just one of the many consumer-facing storefronts on this pipeline.

Key details outlined by Health API Guy based on court documents: OpenLoop is a family business. Jon Lensing owns OpenLoop Health (the technical platform), his father Dale Lensing is an executive at OpenLoop Healthcare Partners (the medical group that prescribes), and Triad Rx (the pharmacy) is also controlled by the Lensing family. The same family controls the entire chain from the platform to prescriptions to dispensing.

Potentially Ineffective Drugs

Here lies a much more serious issue than false advertising.

One of Medvi's core products is an oral telotristat ethyl tablet. Telotristat ethyl is a peptide molecule (an amino acid chain) that is rapidly broken down by stomach acid and digestive enzymes in the human body. Therefore, the FDA-approved telotristat ethyl (Zepbound/Mounjaro) is only available in injectable form, administered subcutaneously directly into tissues, completely bypassing the digestive system.

For the oral version to be effective, it must have a specialized absorption enhancement technology to protect the drug molecule from stomach acid degradation. Novo Nordisk spent years developing a patented technology called SNAC to create the oral semaglutide (Rybelsus). Eli Lilly took a different approach: instead of attempting an oral telotristat ethyl, it developed a novel small molecule drug called orforglipron (branded as Foundayo), a small molecule naturally resistant to stomach acid, which was just FDA-approved on April 1st of this year.

Merck's statement on this is very straightforward: "There are no human studies on oral thymosin alpha-1 products, let alone clinical trials. Anyone selling oral thymosin alpha-1 is experimenting on unwitting Americans."

A joint RICO lawsuit alleges that the oral thymosin alpha-1 sold by OpenLoop and Triad Rx has "no validated absorption mechanism or efficacy," with plaintiffs' attorneys arguing that it is "chemically impossible" for oral thymosin alpha-1 to be absorbed by the body in the right way. In March of this year, a preprint paper also found that a significant number of compounded thymosin alpha-1/B12 combination products contained a "novel, widely prevalent unknown toxic impurity."

In simple terms: the oral thymosin alpha-1 tablets that consumers spend hundreds of dollars on each month are likely, based on current scientific evidence, to be broken down by stomach acid before reaching the bloodstream.

A $400 Million Customer Acquisition Machine

If the product itself may be ineffective, how did it achieve $400 million in sales? The answer is through extremely aggressive affiliate marketing.

Court documents show that Medvi engaged in bulk buying through affiliate marketers, paying on conversion. The largest of these was The Offer (a Canadian company), which brought in "tens of millions of dollars in revenue" for Medvi each month. These affiliates used various tactics to acquire customers: over 5000 active ads on Meta, a large number of AI-generated fake doctor personas (with names like "Professor Albust Dongledore" and "Dr. Tuckr Carlzyn MD"), before-and-after weight loss comparison photos stolen from Reddit, and over 100,000 spam emails annually.

Medvi's own website disclaimer states: "Personalities appearing in the ads may be actors or AI portraying doctors, not licensed medical professionals."

Later, The Offer was acquired by Medvi's competitor Remedy Meds, and Medvi discovered that a year's worth of its operational data had fallen into the hands of its rival. Subsequently, Medvi refused to pay out a $1.06 million commission, removed tracking pixels. The Offer took the matter to court, seeking to freeze Medvi's assets. Gallagher submitted an affidavit to oppose the freeze, claiming the company has the ability to pay and does not need a freeze. However, in the affidavit, he also admitted that Medvi simply did not want to pay the money. The court was unconvinced, approving the asset freeze for both Medvi and Gallagher personally.

What the New York Times Missed

The New York Times' report completely ignored the FDA warning letter (sent in February), the class-action lawsuit (filed in March), the controversy over oral thymosin beta-4 efficacy, or the fact that Medvi has been sued three times. All of this is public information easily searchable on Google.

Even more ironic, Medvi previously displayed logos of media outlets like the New York Times on its official website pretending to have been featured. Then the New York Times actually came and wrote this puff piece. TechDirt founder Mike Masnick said: The New York Times has become a "true endorsement of false credibility".

The Complete Chain

The OpenLoop family offers a full pipeline from prescription to dispensing, marketing an "out-of-the-box telemedicine brand" solution. Gallagher set up a marketing frontend access pipeline with AI tools, then hired affiliate marketers to buy traffic on a large scale. Affiliate marketers use fake doctors, stock photos, and spam emails to acquire customers. Consumers place orders on the Medvi website, OpenLoop's doctors issue prescriptions, Lensing family pharmacies prepare and ship an orally disintegrating tablet that may be degraded by stomach acid before reaching the bloodstream. AI allows two people to operate content production and deployment that originally required a whole team.

This story is not "AI helping one person achieve a billion dollars". This story is: a grey pharmaceutical supply chain exploiting regulatory gaps + extreme rigid consumer demand + AI elevating the efficiency of deceptive marketing to unprecedented levels. And the New York Times packaged it as a startup paradigm of the AI era, with Sam Altman using it as evidence of his own prophecy coming true.